STADA postpones press and analyst conference on full year figures 2016 to March 29, 2017
- Press Release
- Investor News
Bad Vilbel, March 21, 2017 –
Today, on March 21, 2017, the Executive Board of STADA Arzneimittel AG informed the public that the press and analyst conference on full year figures 2016 have been rescheduled to Wednesday, March 29, 2017.
The reason for this decision is the fact that in the process of the consolidated financial statements a reassessment of a transaction was undertaken. This reassessment will be aligned with auditors before closing the consolidated balance sheet. The reassessment regarding consolidation matters might result in an impact on adjusted EBITDA in the mid-single-digit million euro range and in an impact on sales in the low double-digit million euro range. In total, the Executive Board does not expect any material changes in the full year figures 2016. Guidance for 2017 remains unchanged.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2015, STADA achieved Group sales of Euro 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 389.4 million and adjusted net income of Euro 165.8 million. As of December 31, 2015, STADA employed 10,532 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org